CN110770344A - shRNA表达框、携带其的多核苷酸序列及其应用 - Google Patents

shRNA表达框、携带其的多核苷酸序列及其应用 Download PDF

Info

Publication number
CN110770344A
CN110770344A CN201880034603.XA CN201880034603A CN110770344A CN 110770344 A CN110770344 A CN 110770344A CN 201880034603 A CN201880034603 A CN 201880034603A CN 110770344 A CN110770344 A CN 110770344A
Authority
CN
China
Prior art keywords
sequence
plasmid
shrna
expression cassette
aav
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880034603.XA
Other languages
English (en)
Inventor
王超
张婷婷
蒋立新
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Solobio Genetechnology Co Ltd
Original Assignee
Shutaishen Beijing Biopharmaceutical Co Ltd
Beijing Sannuo Jiayi Biological Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shutaishen Beijing Biopharmaceutical Co Ltd, Beijing Sannuo Jiayi Biological Technology Co Ltd filed Critical Shutaishen Beijing Biopharmaceutical Co Ltd
Publication of CN110770344A publication Critical patent/CN110770344A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171—Demonstrated in vivo effect

Abstract

一种shRNA表达框、携带所述表达框的多核苷酸序列及其应用。按照5’‑3’的顺序，所述shRNA表达框依次含表达shRNA的DNA序列及填充序列，所述shRNA表达框序列长度接近野生型AAV基因组长度。

Description

PCT国内申请，说明书已公开。

Claims (29)

  1. PCT国内申请，权利要求书已公开。
CN201880034603.XA 2017-03-31 2018-03-26 shRNA表达框、携带其的多核苷酸序列及其应用 Pending CN110770344A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710210863 2017-03-31
CN2017102108635 2017-03-31
PCT/CN2018/080480 WO2018177244A1 (zh) 2017-03-31 2018-03-26 shRNA表达框、携带其的多核苷酸序列及其应用

Publications (1)

Publication Number Publication Date
CN110770344A true CN110770344A (zh) 2020-02-07

Family

ID=63674215

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880034603.XA Pending CN110770344A (zh) 2017-03-31 2018-03-26 shRNA表达框、携带其的多核苷酸序列及其应用

Country Status (6)

Country Link
US (1) US20210108197A1 (zh)
EP (1) EP3613856A4 (zh)
CN (1) CN110770344A (zh)
SG (1) SG11201909136PA (zh)
TW (1) TW201837173A (zh)
WO (1) WO2018177244A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112107677A (zh) * 2020-07-31 2020-12-22 江苏省人民医院（南京医科大学第一附属医院） EFTUD2应用及Epro-LUC-HepG2建模法
WO2023125823A1 (zh) * 2021-12-31 2023-07-06 北京三诺佳邑生物技术有限责任公司 靶向HIV的siRNA和shRNA及其相应的组合、表达盒、细胞及其应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023009276A2 (pt) * 2020-11-16 2024-02-06 Beijing Solobio Genetechnology Co Ltd Vírus recombinantes adenoassociados (raav), composição e uso do raav
AU2022218196A1 (en) * 2021-02-05 2023-08-10 Maze Therapeutics, Inc. Vectors comprising stuffer polynucleotide sequences

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1580070A (zh) * 2003-08-06 2005-02-16 北京三诺佳邑生物技术有限责任公司 一组抗hbv感染及防治乙型肝炎的核苷酸序列及其应用
US20070027099A1 (en) * 2003-05-19 2007-02-01 Lin Marie C Gene therapy of HBV infection via adeno-associated viral vector mediated long term expression of small hairpin RNA (shRNA)
WO2014114934A1 (en) * 2013-01-22 2014-07-31 Horizon Discovery Limited Methods for improving the efficiency of gene targeting
CN105612253A (zh) * 2013-03-15 2016-05-25 费城儿童医院 含有填充者/填充物多核苷酸序列的载体及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8202979B2 (en) * 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
ES2874298T3 (es) 2003-09-30 2021-11-04 Univ Pennsylvania Clados de virus adenoasociados (AAV), secuencias, vectores que contienen el mismo, y usos de los mismos
WO2009137006A2 (en) 2008-04-30 2009-11-12 The University Of North Carolina At Chapel Hill Directed evolution and in vivo panning of virus vectors
US9790502B2 (en) * 2010-10-28 2017-10-17 Benitec Biopharma Limited HBV treatment
CN103040450A (zh) * 2011-10-14 2013-04-17 李玲 便捷式自身消毒血压计
CA2922500A1 (en) * 2013-08-27 2015-03-05 Research Institute At Nationwide Children's Hospital Products and methods for treatment of amyotrophic lateral sclerosis
MX2017010370A (es) * 2015-02-10 2017-12-14 Genzyme Corp Suministro mejorado de particulas virales al cuerpo estriado y al cortex.
CA3021949C (en) * 2015-04-24 2023-10-17 University Of Massachusetts Modified aav constructs and uses thereof
AU2017234929A1 (en) * 2016-03-18 2018-10-04 The Children's Hospital Of Philadelphia Therapeutic for treatment of diseases including the central nervous system
KR20190064590A (ko) * 2016-09-14 2019-06-10 베니텍 바이오파마 리미티드 비-기능성 t-세포 수용체 (tcr)를 갖는 t-세포를 생산하기 위한 시약, 이를 포함하는 조성물 및 이의 용도

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070027099A1 (en) * 2003-05-19 2007-02-01 Lin Marie C Gene therapy of HBV infection via adeno-associated viral vector mediated long term expression of small hairpin RNA (shRNA)
CN1580070A (zh) * 2003-08-06 2005-02-16 北京三诺佳邑生物技术有限责任公司 一组抗hbv感染及防治乙型肝炎的核苷酸序列及其应用
WO2014114934A1 (en) * 2013-01-22 2014-07-31 Horizon Discovery Limited Methods for improving the efficiency of gene targeting
CN105612253A (zh) * 2013-03-15 2016-05-25 费城儿童医院 含有填充者/填充物多核苷酸序列的载体及其制备方法

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
ALEX MAS MONTEYS等: "Single nucleotide seed modification restores in vivo tolerability of a toxic artificial miRNA sequence in the mouse brain", 《NUCLEIC ACIDS RESEARCH》 *
ALEX MAS MONTEYS等: "Single nucleotide seed modification restores in vivo tolerability of a toxic artificial miRNA sequence in the mouse brain", 《NUCLEIC ACIDS RESEARCH》, vol. 42, no. 21, 20 October 2014 (2014-10-20), pages 13315 - 13327, XP055611100, DOI: 10.1093/nar/gku979 *
DAVID A SUHY等: "Safe, long-term hepatic expression of anti-HCV shRNA in a nonhuman primate model", 《MOLECULAR THERAPY》, vol. 20, no. 9, pages 1737 - 1749 *
DIRKGRIMM等: "Adeno-Associated Virus Vectors for Short Hairpin RNA Expression", 《METHODS IN ENZYMOLOGY》 *
DIRKGRIMM等: "Adeno-Associated Virus Vectors for Short Hairpin RNA Expression", 《METHODS IN ENZYMOLOGY》, vol. 392, 12 January 2005 (2005-01-12), pages 381 - 405, XP008052578, DOI: 10.1016/S0076-6879(04)92023-X *
M. MACHITANI等: "Improving adenovirus vector-mediated RNAi efficiency by lacking the expression of virus-associated RNAs", 《VIRUS RESEARCH》 *
M. MACHITANI等: "Improving adenovirus vector-mediated RNAi efficiency by lacking the expression of virus-associated RNAs", 《VIRUS RESEARCH》, vol. 178, no. 2, 18 September 2013 (2013-09-18), pages 357 - 363, XP028782568, DOI: 10.1016/j.virusres.2013.09.021 *
MEGAN S. KEISER等: "RNAi prevents and reverses phenotypes induced by mutant human ataxin-1", 《ANNALS OF NEUROLOGY》 *
MEGAN S. KEISER等: "RNAi prevents and reverses phenotypes induced by mutant human ataxin-1", 《ANNALS OF NEUROLOGY》, vol. 80, no. 5, 30 September 2016 (2016-09-30), pages 754 - 765, XP055611079, DOI: 10.1002/ana.24789 *
MERITXELL MORRÓ等: "Pancreatic Transduction by Helper-Dependent Adenoviral Vectors via Intraductal Delivery", 《HUMAN GENE THERAPY》 *
MERITXELL MORRÓ等: "Pancreatic Transduction by Helper-Dependent Adenoviral Vectors via Intraductal Delivery", 《HUMAN GENE THERAPY》, vol. 25, no. 9, 21 July 2014 (2014-07-21), pages 824 - 836 *
ROBIN J. PARKS等: "Effects of stuffer DNA on transgene expression from helper-dependent adenovirus vectors", 《JOURNAL OF VIROLOGY》 *
ROBIN J. PARKS等: "Effects of stuffer DNA on transgene expression from helper-dependent adenovirus vectors", 《JOURNAL OF VIROLOGY》, vol. 73, no. 10, 1 October 1999 (1999-10-01), pages 8027 - 8034, XP002245151 *
SHUMEI ZHONG等: "The recombinant adeno-associated virus vector (rAAV2)-mediated apolipoprotein B mRNA-specific hammerhead ribozyme: a self-complementary AAV2 vector improves the gene expression", 《GENETIC VACCINES AND THERAPY》 *
SHUMEI ZHONG等: "The recombinant adeno-associated virus vector (rAAV2)-mediated apolipoprotein B mRNA-specific hammerhead ribozyme: a self-complementary AAV2 vector improves the gene expression", 《GENETIC VACCINES AND THERAPY》, vol. 2, no. 1, 11 June 2004 (2004-06-11), pages 5, XP021009750, DOI: 10.1186/1479-0556-2-5 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112107677A (zh) * 2020-07-31 2020-12-22 江苏省人民医院（南京医科大学第一附属医院） EFTUD2应用及Epro-LUC-HepG2建模法
WO2023125823A1 (zh) * 2021-12-31 2023-07-06 北京三诺佳邑生物技术有限责任公司 靶向HIV的siRNA和shRNA及其相应的组合、表达盒、细胞及其应用

Also Published As

Publication number Publication date
TW201837173A (zh) 2018-10-16
EP3613856A4 (en) 2020-12-23
SG11201909136PA (en) 2019-10-30
US20210108197A1 (en) 2021-04-15
WO2018177244A1 (zh) 2018-10-04
EP3613856A1 (en) 2020-02-26

Similar Documents

Publication Publication Date Title
US20230313230A1 (en) Methods of packaging multiple adeno-associated virus vectors
US11034974B2 (en) Hairpin MRNA elements and methods for the regulation of protein translation
AU2016362317B2 (en) Scalable methods for producing recombinant Adeno-Associated Viral (AAV) vector in serum-free suspension cell culture system suitable for clinical use
US10829783B2 (en) Multicistronic expression constructs
KR102380265B1 (ko) 변종 ａａｖ 및 조성물, 세포, 기관 및 조직으로의 유전자 전이를 위한 방법 및 용도
KR20200033840A (ko) 개선된 세포 트랜스펙션 및/또는 rAAV 벡터 생산을 위한 증진제
KR20160026841A (ko) 스터퍼/필러 폴리누클레오티드 서열을 포함하는 벡터 및 사용 방법
CN110770344A (zh) shRNA表达框、携带其的多核苷酸序列及其应用
US20220154213A1 (en) Bocaparvovirus small noncoding rna and uses thereof
US20220175970A1 (en) Controlled expression of transgenes using closed-ended dna (cedna) vectors
US20230077409A1 (en) Modified u6 promoter system for tissue specific expression
US20210222196A1 (en) Modified aav constructs and uses thereof
WO2022100748A1 (en) Recombinant adeno-associated viruses with enhanced liver tropism and uses thereof
US20220273815A1 (en) Enhanced transduction of aav vectors encoding micrornas
US20230072954A1 (en) Compositions and methods for circular rna expression
WO2023122803A1 (en) Gene therapy for lamin a - associated deficiencies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40015201

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20230308

Address after: Room 401, Building 5, No. 36, Jinghai Second Road, Daxing Economic and Technological Development Zone, Beijing, 100176

Applicant after: BEIJING SOLOBIO GENETECHNOLOGY Co.,Ltd.

Address before: No. 36, Jinghai 2nd Road, Beijing Economic and Technological Development Zone, Beijing, 100176

Applicant before: STAIDSON(BEIJING) BIOPHARMACEUTICALS Co.,Ltd.

Applicant before: BEIJING SOLOBIO GENETECHNOLOGY Co.,Ltd.

TA01 Transfer of patent application right